These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2388676)

  • 1. Mitotane therapy of adrenocortical carcinoma.
    Haak HR; van Seters AP; Moolenaar AJ
    N Engl J Med; 1990 Sep; 323(11):758. PubMed ID: 2388676
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adrenocortical carcinoma and its treatment with mitotane. Description of a case].
    Parma A; D'Agnolo B
    Minerva Med; 1991 Dec; 82(12):883-8. PubMed ID: 1780099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
    Lecka A; Ginalska-Malinowska M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant mitotane for adrenocortical cancer--working through uncertainty.
    Terzolo M; Fassnacht M; Ciccone G; Allolio B; Berruti A
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1879-80. PubMed ID: 19494162
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant mitotane in adrenocortical carcinoma.
    Dickstein G; Shechner C; Nativ O
    N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
    Schteingart DE
    N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
    Huang H; Fojo T
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3730-2. PubMed ID: 18842984
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant mitotane in adrenocortical carcinoma.
    Bertherat J; Coste J; Bertagna X
    N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
    Berruti A; Fassnacht M; Baudin E; Hammer G; Haak H; Leboulleux S; Skogseid B; Allolio B; Terzolo M
    J Clin Oncol; 2010 Aug; 28(23):e401-2; author reply e403. PubMed ID: 20567001
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant mitotane in adrenocortical carcinoma.
    Machens A; Dralle H
    N Engl J Med; 2007 Sep; 357(12):1258-9; author reply 1259. PubMed ID: 17891837
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mitotane in the treatment of adrenal carcinoma].
    Sane T
    Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Two years later.
    Kasperlik-Załuska AA; Migdalska BM; Makowska AM
    Cancer; 1996 Oct; 78(7):1520-1. PubMed ID: 8839564
    [No Abstract]   [Full Text] [Related]  

  • 14. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
    Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
    Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
    [No Abstract]   [Full Text] [Related]  

  • 15. [Complete and lasting remission of a metastatic malignant adrenocortical carcinoma under treatment with OP'DDD alone].
    Remond S; Bardet S; Charbonnel B
    Presse Med; 1992 May; 21(18):865. PubMed ID: 1535153
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.
    Luton JP; Cerdas S; Billaud L; Thomas G; Guilhaume B; Bertagna X; Laudat MH; Louvel A; Chapuis Y; Blondeau P
    N Engl J Med; 1990 Apr; 322(17):1195-201. PubMed ID: 2325710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete remission of metastasized adrenocortical carcinoma under o,p'-DDD.
    Kornely E; Schlaghecke R
    Exp Clin Endocrinol; 1994; 102(1):50-3. PubMed ID: 8005209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
    Barzon L; Fallo F; Sonino N; Daniele O; Boscaro M
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1488-9. PubMed ID: 10199802
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.
    Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S
    Therapie; 2015; 70(6):545-6. PubMed ID: 26242497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.